



Aerospan[®] (flunisolide) – Revised indication

- On June 23, 2017, the [FDA approved](#) a revision to the indication for [Aerospan \(flunisolide\)](#). Information regarding asthma patients requiring oral corticosteroid therapy was removed.
 - Previously, Aerospan was also indicated for asthma patients requiring oral corticosteroid therapy, where adding Aerospan may reduce or eliminate the need for oral corticosteroids.
- Aerospan is now only indicated for the maintenance treatment of asthma as prophylactic therapy in adult and pediatric patients 6 years of age and older.
 - Aerospan is not indicated for the relief of acute bronchospasm and not indicated for children < 6 years of age.
- The dosing section was also revised to state that dosing is based on previous asthma therapy and disease severity.
 - Dosing information for patients receiving chronic oral corticosteroid therapy was removed.



OptumRx[®] specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum[®] company — a leading provider of integrated health services. Learn more at [optum.com](#).

All Optum[®] trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews[®] is published by the OptumRx Clinical Services Department.

©2017 Optum, Inc. All rights reserved.